Endo International PLC (NASDAQ:ENDP) shares dropped 3.2% during mid-day trading on Friday . The company traded as low as $17.30 and last traded at $17.43, with a volume of 1,866,191 shares trading hands. The stock had previously closed at $18.00.

ENDP has been the topic of a number of research reports. JMP Securities initiated coverage on shares of Endo International PLC in a research report on Thursday, April 21st. They set an “outperform” rating and a $56.00 target price on the stock. Goldman Sachs Group Inc. initiated coverage on shares of Endo International PLC in a research report on Monday, June 6th. They set a “neutral” rating and a $20.00 target price on the stock. Stifel Nicolaus dropped their target price on shares of Endo International PLC from $90.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday, May 6th. TheStreet downgraded shares of Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, March 29th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $61.00 target price (down previously from $65.00) on shares of Endo International PLC in a research report on Monday, April 18th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and ten have given a buy rating to the stock. Endo International PLC has a consensus rating of “Hold” and an average price target of $40.32.

The firm’s 50-day moving average is $16.85 and its 200-day moving average is $31.71. The company’s market capitalization is $3.90 billion.

Endo International PLC (NASDAQ:ENDP) last released its quarterly earnings data on Thursday, May 5th. The company reported $1.08 EPS for the quarter, topping the consensus estimate of $1.04 by $0.04. The business earned $963.54 million during the quarter, compared to the consensus estimate of $960.96 million. During the same quarter in the previous year, the business posted $1.17 earnings per share. Endo International PLC’s quarterly revenue was up 34.9% compared to the same quarter last year. Equities research analysts forecast that Endo International PLC will post $4.56 EPS for the current year.

In other Endo International PLC news, insider Paul Campanelli acquired 13,000 shares of Endo International PLC stock in a transaction that occurred on Tuesday, May 10th. The stock was bought at an average cost of $15.53 per share, for a total transaction of $201,890.00. Following the acquisition, the insider now owns 201,069 shares of the company’s stock, valued at $3,122,601.57. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Arthur J. Higgins acquired 5,000 shares of Endo International PLC stock in a transaction that occurred on Wednesday, May 11th. The stock was acquired at an average price of $13.80 per share, with a total value of $69,000.00. Following the completion of the acquisition, the director now directly owns 50,623 shares in the company, valued at approximately $698,597.40. The disclosure for this purchase can be found here.

A number of large investors have added to or reduced their stakes in the company. Cibc World Markets Corp acquired a new stake in Endo International PLC during the fourth quarter valued at approximately $47,081,000. Mcclain Value Management LLC increased its stake in Endo International PLC by 45.6% in the fourth quarter. Mcclain Value Management LLC now owns 334,302 shares of the company’s stock worth $20,466,000 after buying an additional 104,705 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock worth $16,737,000 after buying an additional 12,234 shares in the last quarter. Finally, Advantus Capital Management Inc increased its stake in Endo International PLC by 2.4% in the fourth quarter. Advantus Capital Management Inc now owns 19,971 shares of the company’s stock worth $1,223,000 after buying an additional 476 shares in the last quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.